It’s not much, but it’s something.

I was looking for a bit of good news, and I found some in Bristol-Myers Squibb Co. BMY

4-28-2-16     “Bristol-Myers Squibb Co. (NYSE: BMY) released its first-quarter financial results before the markets opened on Thursday. The company said it had $0.74 in earnings per share (EPS) on $4.4 billion in revenue. That compares to consensus estimates from Thomson Reuters that called for $0.65 in EPS on revenue of $4.25 billion. In the same period of last year, it posted EPS of $0.71 and $4.04 billion in revenue.”

During this quarter, U.S. revenues increased 24% to $2.5 billion year over year. International revenues decreased 7%. When adjusted for foreign exchange impact, international revenues decreased 2%.”

Sales of Opdivo surged 40% to $704m in the quarter. Sales of Eliquis more than doubled to $664m, and its hepatitis C franchise increased by 62%.

Revenues increased by 9% YoY to $4.39b.

BMY increased its EPS to $2.50 to $2.60 from the previous range of $2.30 to $2.40